[Systemic Lupus Erythematosus (SLE) - New Classification Criteria].
The work on new classification criteria for SLE supported by both EULAR and ACR has led to the reconfirmation that almost all SLE patients are ANA positive. The criteria developed now rely on ANA as an entry criterion and weighted additive criteria. Remission criteria have reached international consensus, which combine the absence of inflammatory activity with glucocorticoids of not higher than 5 mg prednisolone/prednisone q. d. This is also meant to reduce the excessive risk of atherosclerosis, where ASS and moderate alcohol consumption appear to be helpful. New insight into therapeutics found that visual impairment appears to be very rare under hydroxychloroquine. Mycophenolate has now been shown to be superior to azathioprine in a controlled trial. The weekly s. c. formulation of belimumab has been approved. A successful phase II study of anifrolumab, targeting the receptor for all type I interferons, holds promise for improving the therapeutic armamentarium.